Monitor Jideytro launch trajectory and prescription data over next 2-3 quarters to gauge market penetration. The next major pipeline catalyst is the neladalkib PDUFA on November 27, 2026, which could further derisk the Nuvalent acquisition thesis. Ris-Rez phase III data in small-cell lung cancer from Hansoh Pharma also warrants attention.
Price Chart
Executive Summary
GSK announced FDA approval of Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, ahead of the original PDUFA date of September 18, 2026. This is GSK's first approved lung cancer therapy and the first product from the recently completed Nuvalent acquisition, validating the deal's strategic rationale. The approval is based on the ARROS-1 phase I/II trial (ORR 44%, 12-month DOR rate 69%) and adds a targeted option for an oncogenic driver with ~50,000 annual diagnoses worldwide.
Key Facts
- FDA approved Jideytro (zidesamtinib) for ROS1-positive locally advanced or metastatic NSCLC after prior ROS1 TKI
- Approval granted ahead of original target action date (Sept 18, 2026) under Breakthrough Therapy and Orphan Drug designations
- ARROS-1 trial showed ORR 44% (95% CI 34-53%) in pre-treated population (n=117); 12-month DOR rate 69%
- Jideytro is GSK's first lung cancer approval and first asset from the recently completed Nuvalent acquisition
- Additional Nuvalent pipeline assets: neladalkib (NVL-655) for ALK-altered NSCLC under FDA review (PDUFA Nov 27, 2026); NVL-330 for HER2-altered NSCLC
- Positive phase III data for risvutatug rezetecan (Ris-Rez) in relapsed small-cell lung cancer recently reported by licensor Hansoh Pharma
Financial Impact
Near-term revenue contribution likely modest for a $103B company given ROS1+ NSCLC represents ~1-2% of lung cancer cases; strategic value is higher as it validates the Nuvalent acquisition and expands GSK's oncology pipeline into lung cancer.
Risk Factors
- Competition from established ROS1 inhibitors (entrectinib, repotrectinib) with earlier-line approvals
- Pricing and reimbursement headwinds in a concentrated targeted therapy market
- Adverse event profile (edema, peripheral neuropathy, fatigue) may limit adoption vs. better-tolerated alternatives
- Launch execution risk given GSK's limited prior experience in lung cancer commercialisation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006789 |
| Document: 0001654954-26-006789-index-headers.html | 0001654954-26-006789 |
| Document: 0001654954-26-006789-index.html | 0001654954-26-006789 |
| Document: 0001654954-26-006789.txt | 0001654954-26-006789 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access